Tags : Dynavax

Clinical Trials COVID-19

Clover and Dynavax Plan to Initiate P-II/III Trial for Adjuvanted

Shots: Clover plans to initiate a global P-II/III efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the H1’2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 Additionally, Clover discontinued their partnership with GSK to evaluate the S-Trimer vaccine candidate with GSK’s pandemic adjuvant […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 20 -24, 2020)

1. Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine Published: Apr 23, 2020 | Tags: Sanofi, Receives, US, FDA, Approval, MenQuadfi, Meningococcal, MenACWY, Conjugate Vaccine 2.  Takeda to Divest Select OTC and Non-Core Assets in Europe to Orifarm for $670M Published: Apr 24, 2020 | Tags: Takeda, Divest, Select OTC and […]Read More

COVID-19 Pharma

Dynavax Signs an Agreement with Sinovac to Develop a Vaccine

Shots: The collaboration will assess the combination of Dynavax’s advanced adjuvant, CpG 1018 with Sinovac’s chemically inactivated coronavirus vaccine candidate Dynavax’s CpG 1018 is the adjuvant used in HEPLISAV-B, the FDA’s approved vaccine for hepatitis B. It was developed to increase HEPLISAV-B vaccine’s immune response CpG 1018 provides a technology and a safety database to […]Read More